hotspot -WSS

hotspot

author：comprehensive 2025-09-02 22:07:21 - browse：5

Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

For more on what we cover, here’s more on Gilead; here’s the news on Inhibrx; here’s the latest on biotech venture capital; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

WSS

Independent physicians launch a new lobbying group

Having children helps parents live longer, especially after age 80

Why don't Americans have at

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Bernie Sanders gets little from pharma CEOs on drug prices

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

hotspot

hotspot

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Juul documents reveal insider tactics on political lobbying

Walensky prepares to leave CDC — and Congress — behind

Resistance to opioid

Heart attack and stroke risk calculators need revising

The surgeon had a dilemma only a Nazi medical text could resolve

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How digital therapeutics firms are pivoting after Pear's bankruptcy

Wildfire smoke exposes gaps in outdoor worker protections

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

leisure time

Report cites 'urgent' need to recruit more diverse clinical trial participants

Tome Biosciences co

Biotech venture capitalists face new demands from investors

The surgeon had a dilemma only a Nazi medical text could resolve

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

EU regulator recommends expanding Mounjaro approval to obesity

hotspot

focus

entertainment

hotspot